Is ANIK or CERS more profitable?

Cerus has a net margin of -4.41% compared to Anika Therapeutics' net margin of -9.52%. Anika Therapeutics' return on equity of -5.90% beat Cerus' return on equity. Company Net Margins Return on Equity Return on Assets Anika Therapeutics -9.52% -5.90% -4.52% Cerus -4.41% -15.18% -4.38%

Does the media prefer ANIK or CERS?

In the previous week, Cerus had 6 more articles in the media than Anika Therapeutics. MarketBeat recorded 7 mentions for Cerus and 1 mentions for Anika Therapeutics. Cerus' average media sentiment score of 0.81 beat Anika Therapeutics' score of 0.00 indicating that Cerus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anika Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cerus 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor OSUR or ANIK?

In the previous week, OraSure Technologies and OraSure Technologies both had 1 articles in the media. OraSure Technologies' average media sentiment score of 0.91 beat Anika Therapeutics' score of 0.00 indicating that OraSure Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OraSure Technologies 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Anika Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate ANIK or UTMD?

Anika Therapeutics currently has a consensus price target of $17.00, indicating a potential upside of 16.44%. Given Anika Therapeutics' higher probable upside, research analysts clearly believe Anika Therapeutics is more favorable than Utah Medical Products. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anika Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Utah Medical Products 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media refer more to ANIK or UTMD?

In the previous week, Anika Therapeutics and Anika Therapeutics both had 1 articles in the media. Anika Therapeutics' average media sentiment score of 0.00 equaled Utah Medical Products'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anika Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Utah Medical Products 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Anika Therapeutics (ANIK) Competitors

$14.60 +0.12 (+0.83%)

Closing price 04:00 PM Eastern

Extended Trading

$14.60 0.00 (-0.03%)

As of 04:10 PM Eastern

Compare

ANIK vs. ANVS, CERS, OSUR, UTMD, and WST

Should you buy Anika Therapeutics stock or one of its competitors? MarketBeat compares Anika Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Anika Therapeutics include Annovis Bio (ANVS), Cerus (CERS), OraSure Technologies (OSUR), Utah Medical Products (UTMD), and West Pharmaceutical Services (WST). These companies are all part of the "medical" sector.

How does Anika Therapeutics compare to Annovis Bio?

Annovis Bio (NYSE:ANVS) and Anika Therapeutics (NASDAQ:ANIK) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, earnings, profitability and analyst recommendations.

Annovis Bio currently has a consensus target price of $13.50, suggesting a potential upside of 654.19%. Anika Therapeutics has a consensus target price of $17.00, suggesting a potential upside of 16.44%. Given Annovis Bio's stronger consensus rating and higher probable upside, analysts plainly believe Annovis Bio is more favorable than Anika Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Anika Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Annovis Bio has a beta of 1.27, suggesting that its share price is 27% more volatile than the broader market. Comparatively, Anika Therapeutics has a beta of 0.23, suggesting that its share price is 77% less volatile than the broader market.

Annovis Bio has a net margin of 0.00% compared to Anika Therapeutics' net margin of -9.52%. Anika Therapeutics' return on equity of -5.90% beat Annovis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annovis Bio	N/A	-318.08%	-215.47%
Anika Therapeutics	-9.52%	-5.90%	-4.52%

In the previous week, Anika Therapeutics had 1 more articles in the media than Annovis Bio. MarketBeat recorded 1 mentions for Anika Therapeutics and 0 mentions for Annovis Bio. Annovis Bio's average media sentiment score of 0.00 equaled Anika Therapeutics'average media sentiment score.

Company	Overall Sentiment
Annovis Bio	Neutral
Anika Therapeutics	Neutral

Anika Therapeutics has higher revenue and earnings than Annovis Bio. Anika Therapeutics is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annovis Bio	N/A	N/A	-$28.85M	-$1.71	N/A
Anika Therapeutics	$112.82M	1.72	-$10.88M	-$0.79	N/A

15.8% of Annovis Bio shares are held by institutional investors. Comparatively, 91.5% of Anika Therapeutics shares are held by institutional investors. 20.8% of Annovis Bio shares are held by company insiders. Comparatively, 12.1% of Anika Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Annovis Bio and Anika Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Anika Therapeutics compare to Cerus?

Anika Therapeutics (NASDAQ:ANIK) and Cerus (NASDAQ:CERS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, earnings, valuation, institutional ownership, analyst recommendations, dividends and risk.

Anika Therapeutics has higher earnings, but lower revenue than Cerus. Cerus is trading at a lower price-to-earnings ratio than Anika Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anika Therapeutics	$112.82M	1.72	-$10.88M	-$0.79	N/A
Cerus	$206.13M	2.53	-$15.63M	-$0.05	N/A

Anika Therapeutics currently has a consensus target price of $17.00, suggesting a potential upside of 16.44%. Cerus has a consensus target price of $4.00, suggesting a potential upside of 53.85%. Given Cerus' stronger consensus rating and higher probable upside, analysts clearly believe Cerus is more favorable than Anika Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anika Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cerus	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Cerus has a net margin of -4.41% compared to Anika Therapeutics' net margin of -9.52%. Anika Therapeutics' return on equity of -5.90% beat Cerus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anika Therapeutics	-9.52%	-5.90%	-4.52%
Cerus	-4.41%	-15.18%	-4.38%

In the previous week, Cerus had 6 more articles in the media than Anika Therapeutics. MarketBeat recorded 7 mentions for Cerus and 1 mentions for Anika Therapeutics. Cerus' average media sentiment score of 0.81 beat Anika Therapeutics' score of 0.00 indicating that Cerus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anika Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cerus	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

91.5% of Anika Therapeutics shares are owned by institutional investors. Comparatively, 78.4% of Cerus shares are owned by institutional investors. 12.1% of Anika Therapeutics shares are owned by company insiders. Comparatively, 3.4% of Cerus shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Anika Therapeutics has a beta of 0.23, meaning that its share price is 77% less volatile than the broader market. Comparatively, Cerus has a beta of 1.76, meaning that its share price is 76% more volatile than the broader market.

Summary

Cerus beats Anika Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Anika Therapeutics compare to OraSure Technologies?

OraSure Technologies (NASDAQ:OSUR) and Anika Therapeutics (NASDAQ:ANIK) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, media sentiment, profitability, dividends, valuation and institutional ownership.

OraSure Technologies presently has a consensus target price of $3.00, indicating a potential downside of 27.71%. Anika Therapeutics has a consensus target price of $17.00, indicating a potential upside of 16.44%. Given Anika Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Anika Therapeutics is more favorable than OraSure Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OraSure Technologies	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Anika Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

93.5% of OraSure Technologies shares are owned by institutional investors. Comparatively, 91.5% of Anika Therapeutics shares are owned by institutional investors. 3.9% of OraSure Technologies shares are owned by insiders. Comparatively, 12.1% of Anika Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, OraSure Technologies and OraSure Technologies both had 1 articles in the media. OraSure Technologies' average media sentiment score of 0.91 beat Anika Therapeutics' score of 0.00 indicating that OraSure Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OraSure Technologies	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Anika Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Anika Therapeutics has a net margin of -9.52% compared to OraSure Technologies' net margin of -66.42%. Anika Therapeutics' return on equity of -5.90% beat OraSure Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OraSure Technologies	-66.42%	-18.57%	-15.71%
Anika Therapeutics	-9.52%	-5.90%	-4.52%

Anika Therapeutics has lower revenue, but higher earnings than OraSure Technologies. Anika Therapeutics is trading at a lower price-to-earnings ratio than OraSure Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OraSure Technologies	$113.02M	2.53	-$68.73M	-$1.04	N/A
Anika Therapeutics	$112.82M	1.72	-$10.88M	-$0.79	N/A

OraSure Technologies has a beta of 1.02, meaning that its stock price is 2% more volatile than the broader market. Comparatively, Anika Therapeutics has a beta of 0.23, meaning that its stock price is 77% less volatile than the broader market.

Summary

Anika Therapeutics beats OraSure Technologies on 9 of the 15 factors compared between the two stocks.

How does Anika Therapeutics compare to Utah Medical Products?

Anika Therapeutics (NASDAQ:ANIK) and Utah Medical Products (NASDAQ:UTMD) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership, media sentiment and risk.

In the previous week, Anika Therapeutics and Anika Therapeutics both had 1 articles in the media. Anika Therapeutics' average media sentiment score of 0.00 equaled Utah Medical Products'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anika Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Utah Medical Products	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

91.5% of Anika Therapeutics shares are owned by institutional investors. Comparatively, 69.6% of Utah Medical Products shares are owned by institutional investors. 12.1% of Anika Therapeutics shares are owned by company insiders. Comparatively, 8.0% of Utah Medical Products shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Utah Medical Products has a net margin of 28.90% compared to Anika Therapeutics' net margin of -9.52%. Utah Medical Products' return on equity of 9.13% beat Anika Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anika Therapeutics	-9.52%	-5.90%	-4.52%
Utah Medical Products	28.90%	9.13%	8.86%

Utah Medical Products has lower revenue, but higher earnings than Anika Therapeutics. Anika Therapeutics is trading at a lower price-to-earnings ratio than Utah Medical Products, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anika Therapeutics	$112.82M	1.72	-$10.88M	-$0.79	N/A
Utah Medical Products	$37.53M	5.71	$11.29M	$3.38	19.90

Anika Therapeutics currently has a consensus price target of $17.00, indicating a potential upside of 16.44%. Given Anika Therapeutics' higher probable upside, research analysts clearly believe Anika Therapeutics is more favorable than Utah Medical Products.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anika Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Utah Medical Products	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Anika Therapeutics has a beta of 0.23, indicating that its stock price is 77% less volatile than the broader market. Comparatively, Utah Medical Products has a beta of 0.37, indicating that its stock price is 63% less volatile than the broader market.

Summary

Utah Medical Products beats Anika Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Anika Therapeutics compare to West Pharmaceutical Services?

Anika Therapeutics (NASDAQ:ANIK) and West Pharmaceutical Services (NYSE:WST) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, valuation, profitability, risk, earnings, institutional ownership and media sentiment.

91.5% of Anika Therapeutics shares are owned by institutional investors. Comparatively, 93.9% of West Pharmaceutical Services shares are owned by institutional investors. 12.1% of Anika Therapeutics shares are owned by insiders. Comparatively, 0.6% of West Pharmaceutical Services shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, West Pharmaceutical Services had 16 more articles in the media than Anika Therapeutics. MarketBeat recorded 17 mentions for West Pharmaceutical Services and 1 mentions for Anika Therapeutics. West Pharmaceutical Services' average media sentiment score of 1.13 beat Anika Therapeutics' score of 0.00 indicating that West Pharmaceutical Services is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anika Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
West Pharmaceutical Services	10 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Anika Therapeutics presently has a consensus target price of $17.00, indicating a potential upside of 16.44%. West Pharmaceutical Services has a consensus target price of $331.91, indicating a potential upside of 3.73%. Given Anika Therapeutics' higher possible upside, research analysts clearly believe Anika Therapeutics is more favorable than West Pharmaceutical Services.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anika Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
West Pharmaceutical Services	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.93

West Pharmaceutical Services has a net margin of 16.85% compared to Anika Therapeutics' net margin of -9.52%. West Pharmaceutical Services' return on equity of 19.03% beat Anika Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anika Therapeutics	-9.52%	-5.90%	-4.52%
West Pharmaceutical Services	16.85%	19.03%	14.06%

Anika Therapeutics has a beta of 0.23, suggesting that its share price is 77% less volatile than the broader market. Comparatively, West Pharmaceutical Services has a beta of 1.18, suggesting that its share price is 18% more volatile than the broader market.

West Pharmaceutical Services has higher revenue and earnings than Anika Therapeutics. Anika Therapeutics is trading at a lower price-to-earnings ratio than West Pharmaceutical Services, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anika Therapeutics	$112.82M	1.72	-$10.88M	-$0.79	N/A
West Pharmaceutical Services	$3.22B	7.02	$493.70M	$7.48	42.78

Summary

West Pharmaceutical Services beats Anika Therapeutics on 15 of the 17 factors compared between the two stocks.

Get Anika Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANIK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANIK vs. The Competition

Export

Metric	Anika Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$194.33M	$3.30B	$6.43B	$12.05B
Dividend Yield	N/A	2.31%	2.67%	5.56%
P/E Ratio	-18.48	18.93	23.75	23.75
Price / Sales	1.72	176.74	480.27	84.51
Price / Cash	N/A	51.45	26.99	37.25
Price / Book	1.47	8.04	10.28	6.78
Net Income	-$10.88M	$23.89M	$3.57B	$337.51M
7 Day Performance	-0.21%	-5.97%	-1.43%	-2.72%
1 Month Performance	-1.15%	2.78%	3.27%	1.87%
1 Year Performance	28.63%	36.26%	23.37%	26.61%

Anika Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ANIK Anika Therapeutics	1.8019 of 5 stars	$14.60 +0.8%	$17.00 +16.4%	+27.6%	$194.33M	$112.82M	N/A	300
ANVS Annovis Bio	2.176 of 5 stars	$1.83 -4.9%	$13.50 +639.7%	-41.1%	$66.52M	N/A	N/A	3
CERS Cerus	3.0414 of 5 stars	$2.84 -6.6%	$4.00 +40.8%	+79.5%	$609.12M	$206.13M	N/A	290	News Coverage
OSUR OraSure Technologies	1.8734 of 5 stars	$4.09 -4.9%	$3.00 -26.7%	+39.8%	$296.05M	$113.02M	N/A	840
UTMD Utah Medical Products	0.8195 of 5 stars	$66.18 -0.4%	N/A	+20.5%	$211.58M	$37.53M	19.58	180	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ANIK) was last updated on 6/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Anika Therapeutics (ANIK) Competitors

ANIK vs. ANVS, CERS, OSUR, UTMD, and WST

How does Anika Therapeutics compare to Annovis Bio?

Summary

How does Anika Therapeutics compare to Cerus?

Summary

How does Anika Therapeutics compare to OraSure Technologies?

Summary

How does Anika Therapeutics compare to Utah Medical Products?

Summary

How does Anika Therapeutics compare to West Pharmaceutical Services?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANIK vs. The Competition

Anika Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Anika Therapeutics (ANIK) Competitors

ANIK vs. ANVS, CERS, OSUR, UTMD, and WST

How does Anika Therapeutics compare to Annovis Bio?

Do analysts rate ANVS or ANIK?

Which has more volatility and risk, ANVS or ANIK?

Is ANVS or ANIK more profitable?

Does the media prefer ANVS or ANIK?

Which has higher valuation and earnings, ANVS or ANIK?

Do insiders & institutionals believe in ANVS or ANIK?

Summary

How does Anika Therapeutics compare to Cerus?

Which has stronger valuation and earnings, ANIK or CERS?

Do analysts prefer ANIK or CERS?

Is ANIK or CERS more profitable?

Does the media prefer ANIK or CERS?

Do insiders & institutionals hold more shares of ANIK or CERS?

Which has more risk & volatility, ANIK or CERS?

Summary

How does Anika Therapeutics compare to OraSure Technologies?

Do analysts rate OSUR or ANIK?

Do insiders & institutionals have more ownership in OSUR or ANIK?

Does the media favor OSUR or ANIK?

Is OSUR or ANIK more profitable?

Which has higher valuation and earnings, OSUR or ANIK?

Which has more risk & volatility, OSUR or ANIK?

Summary

How does Anika Therapeutics compare to Utah Medical Products?

Does the media refer more to ANIK or UTMD?

Do institutionals and insiders have more ownership in ANIK or UTMD?

Is ANIK or UTMD more profitable?

Which has better valuation and earnings, ANIK or UTMD?

Do analysts rate ANIK or UTMD?

Which has more risk & volatility, ANIK or UTMD?

Summary

How does Anika Therapeutics compare to West Pharmaceutical Services?

Do institutionals & insiders have more ownership in ANIK or WST?

Does the media favor ANIK or WST?

Do analysts prefer ANIK or WST?

Is ANIK or WST more profitable?

Which has more volatility and risk, ANIK or WST?

Which has higher earnings and valuation, ANIK or WST?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANIK vs. The Competition

Anika Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools